Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sonoma PharmaceuticalsFRA:O8Z 34 Days Payable is 47.90 as of Mar. 2026, which is 5% below its 10-year median of 50.42. GuruFocus rates FRA:O8Z with a GF Score™ of 34/100 and a GF Value™ of €6.04. The stock has 4 warning signs investors should review. Among 926 Drug Manufacturers companies, Sonoma Pharmaceuticals ranks worse than 76.46% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:O8Z vs YCBD, CVSI, AKAN: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonoma Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Sonoma Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sonoma Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonoma Pharmaceuticals (FRA:O8Z) has a Days Payable of 47.90 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sonoma Pharmaceuticals and its competitors. This is near median its historical median of 50.42. Over the past decade, Sonoma Pharmaceuticals' Days Payable has ranged from 32.27 to 72.07. According to the industry distribution chart, Sonoma Pharmaceuticals ranks #708 out of 926 companies in the Drug Manufacturers industry, placing it in the top 76.5%.
Is Sonoma Pharmaceuticals' Days Payable too high?
Sonoma Pharmaceuticals' current Days Payable of 47.90 is near median its 10-year median of 50.42. Over the past 10 years, this metric has ranged from a low of 32.27 to a high of 72.07. The Drug Manufacturers industry median Days Payable is 90.22. Sonoma Pharmaceuticals' value of 47.90 is 46.9% below this industry median. Based on the distribution chart, Sonoma Pharmaceuticals ranks #708 out of 926 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sonoma Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Sonoma Pharmaceuticals' Days Payable compare to YCBD and CVSI?
According to the Drug Manufacturers industry distribution chart, Sonoma Pharmaceuticals ranks #708 out of 926 companies for Days Payable. This places Sonoma Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 90.22. Sonoma Pharmaceuticals' value of 47.90 is 46.9% below this benchmark. Historically, Sonoma Pharmaceuticals' own Days Payable has ranged from 32.27 to 72.07 over the past decade. While the company's 10-year median is 50.42 vs. the industry median of 90.22, Sonoma Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sonoma Pharmaceuticals's current Days Payable of 47.90 is 46.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sonoma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonoma Pharmaceuticals's current Days Payable is 47.90, which is near median its own 10-year median of 50.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonoma Pharmaceuticals stock overvalued right now?
Sonoma Pharmaceuticals (FRA:O8Z) has a current Days Payable of 47.90. The stock's GF Value™ is €6.04, compared to a current price of €2.72 — trading 55% below its estimated fair value. The current Days Payable is 47.90, which is near median its 10-year median of 50.42 and 46.9% below the Drug Manufacturers industry median of 90.22. Sonoma Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sonoma Pharmaceuticals (FRA:O8Z), the current Days Payable is 47.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonoma Pharmaceuticals (FRA:O8Z) Overvalued in 2026?
Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued.
The current stock price of €2.72 is trading 55% below its estimated GF Value™ of €6.04.
Key valuation signals for FRA:O8Z:
Days Payable: 47.90 (near median its 10-year median of 50.42)
GF Value™: €6.04 vs. price of €2.72 (55% below fair value)
Industry Position: 46.9% below the Drug Manufacturers median (#708 of 926)
No single metric tells the full story. See the FRA:O8Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
34GF Score
Get the complete analysis for FRA:O8Z
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O8Z has been successfully added to your 
